Total medical devices industry cross border deals worth $2.8bn were announced globally for January 2022, with Ardian Holding $1.26bn private equity deal for 70% stake in Biofarma being the sector’s biggest investment, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked an increase of 18.4% over the previous month of $2.39bn and a drop of 58.8% when compared with the last 12-month average of $6.86bn.
In terms of number of cross border deals, the sector saw a rise of 17.86% with 66 deals in January 2022 when compared to the last 12-month average of 56 deals.
In value terms, Europe led the activity with cross border deals worth $1.66bn in January 2022.
medical devices industry cross border deals in January 2022: Top deals
The top five cross border deals accounted for 71.9% of the overall value during January 2022.
The combined value of the top five cross border deals stood at $2.03bn, against the overall value of $2.8bn recorded for the month.
The top five medical devices industry cross border deals of January 2022 tracked by GlobalData were:
1) Ardian Holding $1.26bn private equity deal for 70% stake in Biofarma
2) The $450m acquisition of Triad Life Sciences by ConvaTec Group
3) Smith & Nephew International $135m acquisition deal with Engage Surgical
4) The $100m venture financing of VIRTUE Diagnostics (Suzhou) by Lilly Asia ventures,Morningside Ventures,Oriza Holdings,PerkinElmer Ventures and Sequoia China Investment Management
5) Caesarea Medical Electronics,Clal Insurance Enterprises Holdings,Department of Defence – United States,European Commission,Horizons Ventures,La Maison Partners,Phoenix Insurance,Poalim Equity,Shavit Capital Fund,Social Capital,Touchwood Capital,Union Tech Ventures and Western Technology Investment $93m venture financing deal with MeMed Diagnostics
Verdict deals analysis methodology
This analysis considers only announced and completed cross border deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.